Science and Technology

Author Archive | mariong

January 9, 2015

X-Chem Announces Collaboration with Janssen and Johnson & Johnson Innovation to Advance Novel Candidates to Treat Inflammatory Diseases

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc. (“X-Chem”), a privately held biotechnology company applying its cutting-edge drug discovery platform to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration, which is being facilitated […]

Continue Reading
January 9, 2015

X-Chem Promotes Diala Ezzeddine to Executive Vice President and Chief Business Officer

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that Diala Ezzeddine, Ph.D., has been promoted to executive vice president and chief business officer, effective December 6, 2014.

Continue Reading
December 17, 2014

X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG

WALTHAM, Mass. – December 17, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012.

Continue Reading
December 10, 2014

X-Chem and Alexion Collaborate to Discover Novel Therapeutic Candidates to Treat Patients with Severe and Ultra-Rare Disorders

WALTHAM, MA – December 11th, 2014 – X-Chem, Inc., a biotechnology company focused on the generation of novel small molecule therapeutics using its proprietary DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Alexion (Nasdaq: ALXN), a global leader in the development and commercialization of life-transforming therapies for patients with severe […]

Continue Reading
June 10, 2014

X-Chem Enters into Multi-Target Collaboration with Pfizer Inc.

WALTHAM, Mass. – June 11, 2014 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Pfizer Inc. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.

Continue Reading
February 24, 2014

Bigger is Better

February 24, 2014 | BioCentury | “Bigger is Better” “The vision is that when the library is big enough, molecules that are practically drug candidates will emerge from the primary screen.” [Read full article]

Continue Reading
February 13, 2014

Overview of Recent Progress in Protein-Expression Technologies for Small-Molecule Screening

February 13, 2014 | Journal of Biomolecular Screening | “Overview of Recent Progress in Protein-Expression Technologies for Small-Molecule Screening” Production of novel soluble and membrane-localized protein targets for functional and affinity-based screening has often been limited by the inability of traditional protein-expression systems to generate recombinant proteins that have properties similar to those of their […]

Continue Reading
February 13, 2014

X-Chem Licenses Epigenetic Drug Discovery Program to Bayer Pharma AG

WALTHAM, Mass. – February 13, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved a success milestone with Bayer Pharma AG in the multi-target collaboration the companies established in July 2012.

Continue Reading